Royalty Report: Drugs, Drug Discovery, ribonucleic acid – Collection: 239003

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Drug Discovery
  • ribonucleic acid
  • Disease
  • Biotechnology
  • Therapeutic
  • Diagnostic
  • DNA
  • Cancer
  • Proteins
  • cardiac
  • Respiratory
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 239003

License Grant
The Parties entered into an exclusive worldwide license or sublicense, as applicable, under the Licensee Antisense Patent Rights, to practice Antisense Technology and to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Antisense Products.  Licensee and its Subsidiaries shall have the right to grant sublicenses under the license from Licensor set forth to third parties only to discover, develop, make, have made, use, sell, have sold, offer to sell, import and have imported Licensee Antisense Drugs.
License Property
Antisense Technology shall mean the use of any oligonucleotide or oligonucleotide analog or mimic thereof targeted to a specific sequence of RNA that hybridizes to such sequence and through such hybridization modulates the production of the targeted gene product. The term Antisense Technology shall not include Ribozyme Technology.

US Antisense Patents
5,929,226 – Antisense oligonucleotide alkylphosphonothioates and arylphospohonothioates
5,652,355 – Hybrid oligonucleotide phosphorothioates
6,143,881 – Hybrid oligonucleotide phosphorothioates

Antisense Products shall mean oligonucleotides or oligonucleotide analogs or mimics thereof targeted to a specific sequence of RNA that hybridize to such sequence and through such hybridization modulate the production of the targeted gene product. The term Antisense Products shall not include Ribozymes.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 1340

License Grant
The Canadian Licensee holds an exclusive worldwide License to certain patent rights relating specifically to antisense and related technologies described in patent applications that were pending at the time of the Agreement with Licensor, a Canadian University.

Subsequent patent amendments or advancements to these patents remain as the property of the Licensee, without License rights accruing back to the Licensor.

License Property
Antisense refers to short DNA or RNA sequences, termed oligonucleotides, which are designed to be complementary to a specific gene sequence. The goal is to alter specific gene expression resulting from the binding of the antisense oligonucleotide to a unique gene sequence.

IPSCIO Record ID: 344587

License Grant
Licensor grants to the Canadian Licensee an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and under the Licensor Core Technology Patents, in each case solely to develop, make, have made, use, sell, offer for sale, have sold and import Products.
License Property
Licensor is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to identify and commercialize novel drugs.

Antisense Compound means an oligomeric compound or analog, mimic or mimetic thereof having a sequence that is partially or wholly complementary to the sequence of a messenger RNA (pre-mRNA or mRNA), viral RNA, or noncoding RNA that directly modulates RNA expression.

Product means a pharmaceutical preparation comprising any single TS ASO or Tandem selected by Licensee. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each TS ASO which constitutes the active pharmaceutical ingredient in each Product.

TS ASO means a single-stranded oligonucleotide or an analog thereof that hybridizes to TS mRNA using Watson-Crick base pairing and inhibits production of TS via an RNase-H mechanism.

1. U.S. Patent No. 6,001,1653
2. PCT Publication No. WO 93/13121
3. U.S. Patent. 5,914,396
4. U.S. Patent 61451,991
5. U.S. Patent No. 6,166,197
6. U.S. Patent No. 51919,619
7. U.S. Patent No. 5,962,425
8. U.S. Patent No. 6,143,881
9. U.S. Patent No. 5,969,116
10. U.S. Patent No. 6,346,614
11. U.S. Patent No. 6,399,754
12. U.S. Patent No. 6,326,199

Field of Use
The field of use is the identification of a lead TS ASO targeted to inhibit Thymidylate Synthase.

The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies, antisense inhibition of TS suppressed human tumor cell growth and overcame tumor cell resistance to marketed TS-targeted drugs.

TS is an important target in a wide variety of cancers including, colorectal, breast, stomach, esophageal, head and neck cancers, and mesothelioma; it is of increasing importance in non-small cell lung cancer. In addition to interfering with the effectiveness of chemotherapy, the TS gene may also participate in causing cancer. TS is a target for several chemotherapy agents, including 5-fluorouracil (5-FU), pemetrexed (Alimta®), and raltitrexed (Tomudex®).

IPSCIO Record ID: 301257

License Grant
Licensor and Licensee will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensor-Licensee Exclusive Targets and the Licensee Exclusive Targets. For each Licensor-Licensee Exclusive Target, Licensee will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensor and Licensee will identify and develop Splicing Modulators that modulate the splicing of Licensor-Licensee Exclusive Targets and Licensee Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants to Licensee an exclusive worldwide license to the Splicing Patents solely to research, develop, make and have made, offer for sale, sell, import and export Licensee Exclusive Products.

License Property
Product means an Licensor-Licensee Exclusive Product or an Licensee Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensee owns or controls certain patents related to morpholino chemistry.

Licensor-Licensee Exclusive Product means a Splicing Modulator that modulates an Licensor-Licensee Exclusive Target and that is Covered by the Licensee Patents and/or an Licensor Invention Patent.

Licensee Exclusive Product means a Splicing Modulator that modulates an Licensee Exclusive Target and is Covered by the Splicing Patents and/or an Licensee Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensee Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensor Splicing Patents.

Licensor Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensee Invention Patent and/or Licensor Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensor Invention or an Licensee Invention, as the case may be, and Patents claiming such Inventions will be Licensor Invention Patents or Licensee Invention Patents, respectively.

Licensor-Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 291167

License Grant
Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensee and Licensor will identify and develop Splicing Modulators that modulate the splicing of Licensee-Licensor Exclusive Targets and Licensor Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants Licensee the following licenses
Licensor grants Licensee an exclusive worldwide license to the Licensor Patents solely to research, develop, offer for sale, sell, import and export Licensee-Licensor Exclusive Products.

License Property
Product means an Licensee-Licensor Exclusive Product or an Licensor Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensor owns or controls certain patents related to morpholino chemistry.

Licensee-Licensor Exclusive Product means a Splicing Modulator that modulates an Licensee-Licensor Exclusive Target and that is Covered by the Licensor Patents and/or an Licensee Invention Patent.

Licensor Exclusive Product means a Splicing Modulator that modulates an Licensor Exclusive Target and is Covered by the Splicing Patents and/or an Licensor Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensor Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensee Splicing Patents.

Licensee Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensor Invention Patent and/or Licensee Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensee Invention or an Licensor Invention, as the case may be, and Patents claiming such Inventions will be Licensee Invention Patents or Licensor Invention Patents, respectively.

Licensee-Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 250968

License Grant
For the Exclusive License,  Licensor grants an exclusive, worldwide license, with the right to sublicense, to Licensor Intellectual Property that relates to a Joint p53-PMO Item, solely in the Licensee Field, to research, develop, make, have made, use, import, put into use, modify, distribute, offer for sale, sell and have sold Licensed Licensor IP Products and to practice Licensed Licensor IP Methods during the term of this Agreement.

For the Semi-Exclusive License, Licensor shall grant a semi-exclusive, worldwide license to Licensor Intellectual Property that relates to a Joint p53-PMO Item, solely in the Joint Field and within the context of such joint development activities with Licensor, to research, develop, make, have made, use, import, put into use, modify, distribute, offer for sale, sell and have sold Licensed Licensor IP Products and to practice Licensed Licensor IP Methods during the term of this Agreement.

License Property
The patents licensed include Antisense Oligonucleotides to p53, and, Methods and compositions for selectively treating cancer cells characterized by p53 expression, and, Therapeutic Oligonucleotides targeting human MDR-! and MRP Genes, and, Methods and compositions for treatment of cancer using Oligonucleotides, and, Methods and Compositions for Cellular Reprogramming.

p53 is a protein.  PMO refers to  phosphorodiamidate morpholino oligomer chemistry.

Antisense drugs targeting p53 is a well-studied human protein that controls cellular response to genetic damage.

Field of Use
Licensees main field of interest in p53-PMO technology is as a potential target for antiviral therapies, and the Parties wish to cooperate in the development and commercialization of therapies using p53-PMO technology in other fields.

IPSCIO Record ID: 383599

License Grant
For the Product License, Licensor grants an exclusive license, with the limited right to sublicense, under the Licensed IP to research, develop, make, have made, use, sell, offer for sale, have sold, import and export Products in the Territory for therapeutic purposes.

For the Limited Right to Sublicense, the Product License is sublicensable only in connection with a sublicense of a Product to any Affiliate of Licensee or to any Third Party,

License Property
Licensor has intellectual property to advance mipomersen and related compounds targeting apoB.

Mipomersen means mipomersen sodium, including all pharmaceutically acceptable salts, solvates, hydrates, hemihydrates, metabolites, pro-drug forms, stereoisomers, enantiomers, racemates and all optically active forms thereof.

apoB means apolipoprotein B.

Product means all pharmaceutical compositions, formulations, dosage forms, delivery systems and presentations that contain Mipomersen or any Follow-On Compound as an active ingredient.

ASO Product any preparation in final form for sale by prescription, over-the-counter or any other method for any indication, including human or animal use, which contains one or more oligonucleotides or an analog thereof that  selectively modulates protein synthesis at the nucleic acid level through the binding of such oligonucleotide to a complementary sequence.

FH means familial hypercholesterolemia.

Licensed Product Patents means the Shortmer Patent, and any Patent Controlled by Isis during the Term, including any Licensor Program Patents and Joint Patents, claiming nucleic acids that hybridize to a nucleic acid molecule encoding apoB, the sequence of apoB. the specific composition of matter of a Product, or methods of using Product as a therapeutic, methods of using Product to modulate apoB, and methods of using the Product to inhibit expression of apoB- and also claiming or describing (x) nucleic acids that hybridize to a nucleic acid molecule encoding a gene target other than apoB or ( y) methods of using such nucleic acids as a therapeutic or to modulate a gene target other than apoB.

Field of Use
The field of use is to treat homozygous familial hypercholesterolemia.  Homozygous familial hypercholesterolemia is a disorder where it is hard for your body to remove LDL 'bad' cholesterol from your blood. The disease raises your chances of a heart attack at an early age, but drugs and other treatments can lower your risk.

Licensee will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes novel antisense technology.  Mipomersen, formerly ISIS 301012, is a lipid-lowering drug targeting apolipoprotein B-100. Currently in phase 3 development, mipomersen has been shown in phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with current standard lipid-lowering drugs, enabling more patients to achieve lipid targets.

IPSCIO Record ID: 300745

License Grant
Licensor grants the Japanese Licensee a license under and to Licensor Technology to Develop and Commercialize the Licensed Product in the Field in the Licensee Territory. Such license is exclusive for the Royalty Term of the Licensed Product in each country in the Licensee Territory, and shall thereafter be a non-exclusive, fully-paid license to Develop, Manufacture and Commercialize the Licensed Product in the Field in such country.

For the Manufacturing License, Licensor grants a non-exclusive license under Licensor Technology solely for the purpose of Manufacturing the Licensed Product for the Licensee Territory and Licensee grants Licensor a non-exclusive license under Licensee Technology to Manufacture the Licensed Product.

License Property
Licensor owns or controls certain fundamental intellectual properties relating to RNA interference, and is developing therapeutic products targeting respiratory syncytial virus (RSV) that function through RNA interference, including the proprietary Licensor product known as ALN-RSV01.

Antisense Product means a single-stranded oligonucleotide or analog thereof having a specific sequence that inhibits protein synthesis at the nucleic acid level by specifically binding to the sequence of a messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing selective inhibition of gene expression.

The patents include, but are not limited to; RNA interference is mitigated by 21 and 22nt small RNAs;  RNA interference mediating small RNA molecules;  RNA sequence-specific mediators of RNA interference; and, Inhaled treatment for RSV.

Field of Use
Licensee enters this agreement for the treatment of respiratory infections in humans caused by RSV, in Japan and certain other countries in Asia.
RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract.

IPSCIO Record ID: 27234

License Grant
Licensee entered into that certain License Agreement with the University pertaining to an invention entitled, External Guide Sequences for an RNA Enzyme.
License Property
One of these core technologies is designed to utilize Innovir's proprietary EGS ('External Guide Sequence') Oligozyme technology to direct a cellular ribozyme to disease-causing RNA, so that the ribozyme will cleave the RNA and thus render it inactive. An EGS Oligozyme is a small, chemically modified oligonucleotide segment that binds to a disease-causing RNA to create a structure resembling a type of RNA which is cleaved by a specific ribozyme in cells. This naturally occurring cellular ribozyme, called RNase P, has been harnessed to cleave such newly formed structures, thereby destroying the disease-causing RNA molecules before they can be used to create disease-causing proteins.

Patent No. 5,168,053

Field of Use
The rights granted apply to the Licensed Patents.

IPSCIO Record ID: 204355

License Grant
This amendment clarifies certain definitions and modifies the royalty rates.

In the original restated license, Licensor grants a world-wide exclusive license under Licensed Patents and Licensed Know-How, to make, use, offer to sell, sell and import Licensed Products in the Exclusive Licensed Field.

License Property
Licensor has certain know-how relating to the synthesis of MGB Oligonucleotides, including MGB Oligonucleotides containing modified bases, and the design of sequence-specific probes comprising such oligonucleotides.  MGB Oligonucleotide means Licensed Product comprising an oligonucleotide having a minor-groove binding moiety covalently attached.

The licensed know-how includes chemical structures, manufacturing methods and Algorithms, object code, source code and any other embodiments of methods or processes useful for predicting the melting temperature of MGB Oligonucleotides, whether patented, copyrighted, or not.

Field of Use
The Exclusive Licensed Field means the 5’-Nuclease Assay Field.  The 5’-Nuclease Assay Field means the detection of a nucleic acid sequence based on the cleavage of a nucleic acid probe that is hybridized to the nucleic acid sequence by a 5’ to 3’ nuclease activity of a polymerase enzyme.

IPSCIO Record ID: 380352

License Grant
Licensor grants
— an exclusive license, including the right to sublicense, under the Licensor Patent Rights to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory,
— an exclusive license, including the right to sublicense, to use Licensor Technology and Licensor Confidential Information to the extent reasonably useful for the manufacture, use, sale, offer for sale and importation of the Compound, any Research Compound and any Licensed Product in the Field in the Territory;

Licensor grants a nonexclusive, worldwide license, including the right to sublicense, under the Licensor Patent Rights in the Field, the Licensor Technology in the Field, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import any molecule that is incidental to the manufacture and use of the Compound, any Research Compound, any Licensed Product or any Generic Product.

For the Clinical Development License, Licensor grants an exclusive license, including the right to sublicense, under the Licensor Patent Rights, the Licensor Technology, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product, for any clinical study in the Territory.

For the Research Licenses, without limiting any of the licenses granted, Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term.

License Property
Licensor owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

Compound means ProMuneâ„¢.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensor.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Licensors Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Field of Use
The field of use includes the treatment, Control or prevention of cancer in humans.

ProMune (CPG 7909) is a toll-like receptor 9 (TLR9) agonist delivered by subcutaneous injection for the potential treatment, control and prevention of cancers in humans.

IPSCIO Record ID: 1417

License Grant
The Licensor hereby grants to Licensee of the Netherlands in the License Field in the License Territory
(i) an exclusive, royalty-bearing license under its rights in Patent Rights to make, have made, use, have used, Sell and have Sold Products and Processes; and
(ii) the right to grant sublicenses under the rights granted (a)(i) to Sublicensees.
License Property
Technology relates to a patent family with claims directed to an alternative RNA repair platform that uses an RNA oligonucleotide complex rather than a single stranded oligonucleotide. This patent family includes an issued U.S. patent with a composition of matter claim directed to an RNA oligonucleotide complex containing two specific oligonucleotide sequences for modulating the expression or activity of a CFTR gene product, and an allowed U.S. patent application with method of use claims relating to the treatment of a symptom of cystic fibrosis in a subject by administering to the subject an RNA oligonucleotide complex comprising two oligonucleotides, as well as a composition of matter claim directed to a specific RNA complex for modulating the activity of a CFTR gene product.
Field of Use
License Field shall mean all therapeutic indications in the field of Cystic Fibrosis.

The Licensee was founded in May 2012 with the goal of developing a treatment for cystic fibrosis.

IPSCIO Record ID: 314354

License Grant
By this amendment, the Parties now proceed with unilateral development of OGX-011 and Products.  As of the Amendment Effective Date, the original Collaboration is terminated.

Licensor grants the Canadian Licensee a worldwide, nonexclusive license, with the right to grant sublicenses, under the Licensor Core Technology, Core Technology Patents, Manufacturing Technology and Manufacturing Patents to research, develop, make, have made, use, gain regulatory approval, commercialize, sell, offer for sale, have sold, export and import OGX-011 and Products for all uses.

For Development, Commercialization and Regulatory Responsibilities, Licensee will have sole responsibility, including without limitation sole responsibility for all funding, resourcing and decision making, for all further development and commercialization with respect to OGX-011 and Products.

License Property
Licensor is discovering and developing RNA-targeted therapeutics, and have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics.

OGX-011 is a second generation antisense inhibitor of Clusterin.  Clusterin means the gene target, official symbol CLU, which is also referred to as Testosterone Repressed Prostatic Message -2 (TRPM-2), and Sulphated Glycoprotein2 (SGP-2).

Licensors Core Technology includes the patents and excludes the Manufacturing Technology and Product-Specific Technology.

Field of Use
Licensee is a development stage enterprise committed to the development and commercialization of new cancer therapies. The product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and address treatment resistance by blocking the production of specific proteins which it believes promote survival of tumor cells and are over-produced in response to a variety of cancer treatments.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.